Pyrotinib

Drug Profile

Pyrotinib

Alternative Names: BLTN; Pyrroltinib maleate

Latest Information Update: 06 Dec 2016

Price : $50

At a glance

  • Originator Shanghai Hengrui Pharmaceutical
  • Developer Jiangsu Hengrui Medicine Co.; Tongji University
  • Class Antineoplastics
  • Mechanism of Action Epidermal growth factor receptor antagonists; ERBB 2 receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Breast cancer; Non-small cell lung cancer
  • Phase I Gastric cancer

Most Recent Events

  • 16 Jul 2016 No recent reports of development identified for phase-I development in Breast-cancer (Late-stage disease, Second-line therapy or greater) in China (PO, Tablet)
  • 14 Jul 2016 Jiangsu HengRui Medicine plans a phase II trial for Non-small cell lung cancer (Late-stage disease, Second-line therapy or greater) in China (PO) (NCT02834936)
  • 01 Jul 2016 Phase-II clinical trials in Breast cancer (Combination therapy, Metastatic disease, Second-line therapy or greater, Late-stage disease) in China (PO) (NCT02973737)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top